Safety, tolerability, and efficacy of intranasally-administered detoxified LTh(αK) in mild-to-moderate COVID-19 patients: A randomized, double-blinded, placebo-controlled phase 2 study.

However, the MMRM for the entire study was barely significant ( p = .078), due to the faster recovery of a single case in the placebo group (1/5, 20%) on post-randomization day 3 (Supplementary Figure S2).

also in 875 other papers

However, the improvement in clinical symptoms did not reach statistical significance in this study, possibly due to two factors: first, the mild symptoms associated with Omicron sub-variants and second, the limited number of patients enrolled.

also in 111,027 other papers